Compare DexCom, Inc. (DXCM) vs Workday Inc (WDAY) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Workday (WDAY) trades at $139.81, down 3.49% amid a broader tech selloff, but maintains a bullish technical signal with support at $136 and resistance at $143. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $2.66 versus $2.51, revenue growth to $8.45B in 2025, and a high gross margin of 75.77%. Analyst sentiment remains positive with 55.55% buy ratings and a $157.30 consensus target, though net cash flow turned negative to -$470M in 2025.

WDAY presents a growth opportunity with AI-driven expansion deals and rising earnings estimates, but risks include ongoing cash flow challenges, competitive pressures in HR software, and a lawsuit over AI bias allegations. The stock's current valuation at 44.18x P/E requires sustained execution to justify upside, making it suitable for investors bullish on enterprise software transformation.